Zydus Cadila Healthcare Limited - Product Pipeline

Review 2015 Now Available at iData Insights

Zydus Cadila Healthcare Limited - Product Pipeline Review - 2015 Summary Global Markets Direct s,
Zydus
Cadila Healthcare Limited - Product Pipeline Review - 2015 , provides an overview of the Zydus Cadila Healthcare
Limited s pharmaceutical research and development focus. This report provides comprehensive information on the
current therapeutic developmental pipeline of Zydus Cadila Healthcare Limited s, complete with comparative
analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along
with special features on late-stage and discontinued projects. Global Markets Direct s report features investigational
drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data
and information sourced from Global Markets Direct s proprietary databases, Company/University websites, SEC
filings, investor presentations and featured press releases from company/university sites and industry-specific third
party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes
periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest
set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical
trials registries tracking ensure that the most recent developments are captured on a real time basis. The report
enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class
products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of
data for the indicated disease. Scope - The report provides brief overview of Zydus Cadila Healthcare Limited
including business description, key information and facts, and its locations and subsidiaries - The report reviews
current pipeline of Zydus Cadila Healthcare Limited s human therapeutic division and enlists all their major and
minor projects - The report features product description and descriptive mechanism of action for key pipeline products
along with the product s developmental history and major milestones - Special feature on out-licensed and
partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest
company statement - Latest news and deals relating to the Zydus Cadila Healthcare Limited s pipeline products
Reasons to buy - Evaluate Zydus Cadila Healthcare Limited s strategic position with total access to detailed
information on its product pipeline - Assess the growth potential of Zydus Cadila Healthcare Limited in its therapy
areas of focus - Identify new drug targets and therapeutic classes in the Zydus Cadila Healthcare Limited s R&D
portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by
identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas
of Zydus Cadila Healthcare Limited and exploit collaboration and partnership opportunities - Identify emerging players
with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan
mergers and acquisitions effectively by identifying the most promising pipeline of Zydus Cadila Healthcare Limited Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most
attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued
projects of Zydus Cadila Healthcare Limited and identify potential opportunities in those areas - Avoid Intellectual
Property Rights related issues
Browse Complete Report with TOC @ http://www.idatainsights.com/reports-landing-page.php?id=124192/zyduscadila-healthcare-limited-product-pipeline-review-2015
To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landing-page.php?id=124192/zyduscadila-healthcare-limited-product-pipeline-review-2015
Table of Contents
2 List of Tables
8 List of Figures
8 Zydus Cadila Healthcare Limited Snapshot
9 Zydus Cadila Healthcare Limited Overview
9 Key Information
9 Key Facts

9 Zydus Cadila Healthcare Limited

Research and Development Overview

10 Key Therapeutic Areas

10 Zydus Cadila Healthcare Limited

Pipeline Review

14 Pipeline Products by Stage of Development

14 Pipeline Products

Monotherapy

15 Pipeline Products

Combination Treatment Modalities

16 Pipeline Products

Partnered Products

17 Partnered Products/Combination Treatment Modalities

18 Zydus Cadila Healthcare Limited

Pipeline Products Glance

19 Zydus Cadila Healthcare Limited

Late Stage Pipeline Products

19 Pre-Registration Products/Combination Treatment Modalities

19 Phase III Products/Combination Treatment Modalities
20 Zydus Cadila Healthcare Limited

Clinical Stage Pipeline Products

21 Phase II Products/Combination Treatment Modalities

21 Phase I Products/Combination Treatment Modalities
22 Zydus Cadila Healthcare Limited

Early Stage Pipeline Products

23 IND/CTA Filed Products/Combination Treatment Modalities

23 Preclinical Products/Combination Treatment Modalities
24 Discovery Products/Combination Treatment Modalities
25 Zydus Cadila Healthcare Limited - Unknown Stage Pipeline Products
26 Unknown Products/Combination Treatment Modalities
26 Zydus Cadila Healthcare Limited

Drug Profiles

27 interferon beta-1b
27 Product Description
27 Mechanism of Action
27 R&D Progress
27 MAb-1
28 Product Description
28 Mechanism of Action
28 R&D Progress
28 measles vaccine
29 Product Description
29 Mechanism of Action

29 R&D Progress
29 saroglitazar
30 Product Description
30 Mechanism of Action
30 R&D Progress 30 tetanus vaccine
31 Product Description 31 Mechanism of Action
31 R&D Progress
31 measles + mumps + rubella vaccine
32 Product Description
32 Mechanism of Action
32 R&D Progress
32 ZYH-7 33 Product Description
33 Mechanism of Action
33 R&D Progress 33 PEG-EPO
34 Product Description
34 Mechanism of Action
34 R&D Progress
34 Rabimabs
35 Product Description
35 Mechanism of Action
35 R&D Progress
35 leishmaniasis vaccine
36 Product Description
36 Mechanism of Action
36 R&D Progress
36 rituximab biosimilar
37 Product Description
37 Mechanism of Action
37 R&D Progress
37 ZYAN-1
38 Product Description
38 Mechanism of Action
38 R&D Progress

38 ZYDPLA-1
39 Product Description
39 Mechanism of Action
39 R&D Progress
39 ZYG-19
40 Product Description
40 Mechanism of Action
40 R&D Progress
40 ZYGK-1
41 Product Description
41 Mechanism of Action
41 R&D Progress
41 ZYT-1
42 Product Description
42 Mechanism of Action
42 R&D Progress
42 Biosimilar 4 for Acute Myocardial Infarction, Infertility and Thrombosis
43 Product Description
43 Mechanism of Action
43 R&D Progress
43 Biosimilar 1 for Nephrology and Oncology
44 Product Description
44 Mechanism of Action
44 R&D Progress
44 Biosimilar 2 for Diabetes and Rheumatoid Arthritis
45 Product Description
45 Mechanism of Action
45 R&D Progress
45 Biosimilar 3 for Rheumatoid Arthritis, Acute Myocardial Infarction and Inflammation
46 Product Description
46 Mechanism of Action
46 R&D Progress
46 Biosimilar 5 for Infertility

47 Product Description
47 Mechanism of Action
47 R&D Progress
47 Biosimilar 6 for Infertility
48 Product Description
48 Mechanism of Action
48 R&D Progress
48 Biosimilar 7 for Infertility and Oncology
49 Product Description
49 Mechanism of Action
49 R&D Progress
49 Biosimilar 8 for Oncology
50 Product Description
50 Mechanism of Action
50 R&D Progress
50 Biosimilar for Immunology
51 Product Description
51 Mechanism of Action
51 R&D Progress
51 diphtheria + tetanus + pertussis (whole-cell) + haemophilus influenzae [serotype B] vaccine
52 Product Description
52 Mechanism of Action
52 R&D Progress
52 diphtheria + tetanus + pertussis (whole-cell) vaccine
53 Product Description
53 Mechanism of Action
53 R&D Progress
53 diphtheria + tetanus vaccine
54 Product Description
54 Mechanism of Action
54 R&D Progress
54 haemophilus influenzae [serotype B] vaccine
55 Product Description 55 Mechanism of Action

55 R&D Progress
55 hepatitis A vaccine
56 Product Description
56 Mechanism of Action
56 R&D Progress
56 hepatitis B vaccine
57 Product Description
57 Mechanism of Action
57 R&D Progress
57 hepatitis E vaccine
58 Product Description
58 Mechanism of Action
58 R&D Progress
58 influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (tetravalent, split virion) vaccine
59 Product Description
59 Mechanism of Action
59 R&D Progress
59 influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine
60 Product Description
60 Mechanism of Action
60 R&D Progress
60 Japanese encephalitis vaccine
61 Product Description
61 Mechanism of Action
61 R&D Progress
61 MAb-6
62 Product Description
62 Mechanism of Action
62 R&D Progress
62 MAb-7
63 Product Description
63 Mechanism of Action
63 R&D Progress

63 MAb-8
64 Product Description
64 Mechanism of Action
64 R&D Progress
64 malaria vaccine
65 Product Description
65 Mechanism of Action
65 R&D Progress
65 Vaccine for Cervical Cancer and Genital Warts
66 Product Description
66 Mechanism of Action
66 R&D Progress
66 typhoid vaccine
67 Product Description
67 Mechanism of Action
67 R&D Progress
67 MAb-2
68 Product Description
68 Mechanism of Action
68 R&D Progress
68 MAb-3
69 Product Description
69 Mechanism of Action
69 R&D Progress
69 MAb-4
70 Product Description
70 Mechanism of Action
70 R&D Progress
70 Zydus Cadila Healthcare Limited

Pipeline Analysis

71 Zydus Cadila Healthcare Limited

Pipeline Products by Target

71 Zydus Cadila Healthcare Limited

Pipeline Products by Route of Administration

73 Zydus Cadila Healthcare Limited

Pipeline Products by Molecule Type

74 Zydus Cadila Healthcare Limited

Pipeline Products by Mechanism of Action

75 Zydus Cadila Healthcare Limited

Recent Pipeline Updates

76 Zydus Cadila Healthcare Limited

Dormant Projects

78 Zydus Cadila Healthcare Limited

Company Statement

79 Zydus Cadila Healthcare Limited

Locations And Subsidiaries

82 Head Office
82 Other Locations & Subsidiaries
82 Appendix
85 Methodology
85 Coverage
85 Secondary Research
85 Primary Research
85 Expert Panel Validation
85 Contact Us
85 Disclaimer
Read More @ http://www.idatainsights.com/reports-landing-page.php?id=124192/zydus-cadila-healthcare-limitedproduct-pipeline-review-2015
About Us:
iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research
information aggregator and marketing research consulting firm. We conduct both primary and secondary research.
Our work does not end with research it is also involved in distributing reports for different companies . We provide
actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be
a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that
will make a difference to their bottom line.

Contact Us:
iData Insights
Tel: 1-866-237-2965
Web: http://www.idatainsights.com
Email: info@idatainsights.com

About iData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to
provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our
promise to provide results that are essential to the success of your company. We believe that by doing so, we will
earn the trust of our clients for future projects.